HTR4 and Alzheimer disease: SSP-002392, an orally administered 5-HT4R agonist at a dose of 5 mg/kg, has been shown to enhance the degradation of Aβ by increasing the presence of microglial cells and astrocytes surrounding Aβ deposits in the hippocampus of AD mouse models [23].